| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T64 |
0-39 |
Sentence |
denotes |
Innovative clinical evidence generation |
| T65 |
40-257 |
Sentence |
denotes |
The pandemic has underscored the premium for speed of success and the acceptability by regulators of the use of innovative trial strategies with a quantitative decision‐making framework to support regulatory approval. |
| T66 |
258-549 |
Sentence |
denotes |
We have seen the benefit of streamlining trial protocols and embracing novel trial designs such as platform approaches to simultaneously test multiple assets in the clinic, using historical data for predictive analyses, or borrowing information on placebo/standard of care from other trials. |
| T67 |
550-722 |
Sentence |
denotes |
10 These mechanisms, together with use of real‐world data on external controls and adaptive clinical designs are not new and are increasingly well understood and accepted. |
| T68 |
723-797 |
Sentence |
denotes |
They should be leveraged where similar benefit/ risk considerations apply. |
